Maziar Azadpour, MD
Cardiovascular Disease · Salem, ORNPI 1730131855
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,392 of the $12,165 with a category attached, or 60.8%. 34 manufacturers reported payments, led by Boston Scientific at 31.3% of the total.
Across 279 payments — averaging $43.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$4K
- Medtronic$3K
- Edwards Lifesciences$650
- Boehringer Ingelheim$608
- AstraZeneca$555
- Pfizer$507
- plus $3K from 28 others
What the payments were for
- Travel & lodging$4,54937%
- Food & beverage$7,39261%
- Education$2242%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 32 | $3,812 |
| Medtronic(2 entities) | 24 | $3,160 |
| Edwards Lifesciences | 8 | $650 |
| Boehringer Ingelheim | 22 | $608 |
| AstraZeneca | 28 | $555 |
| Pfizer | 25 | $507 |
| E.r. Squibb & Sons, L.L.C. | 26 | $419 |
| Novartis | 23 | $367 |
| Abbott | 5 | $308 |
| Johnson & Johnson | 15 | $267 |
| Amgen | 10 | $222 |
| Novo Nordisk | 7 | $120 |
| Biotronik Inc. | 2 | $106 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $106 |
| Change Healthcare Technologies, LLC | 1 | $95 |
| Alnylam Pharmaceuticals Inc. | 5 | $94 |
| Sanofi-aventis U.S. LLC | 5 | $82 |
| Merck | 3 | $76 |
| Chiesi USA, Inc. | 3 | $74 |
| Philips North America LLC | 2 | $73 |
| Regeneron Healthcare Solutions, Inc. | 5 | $72 |
| Actelion Pharmaceuticals US, Inc. | 6 | $61 |
| Shockwave Medical, Inc | 1 | $56 |
| Lundbeck LLC | 3 | $55 |
| Lexicon Pharmaceuticals, Inc. | 2 | $44 |
| Penumbra, Inc. | 2 | $35 |
| Irhythm Technologies, Inc. | 1 | $23 |
| CMP Pharma, Inc. | 1 | $20 |
| Bristol Myers Squibb | 1 | $20 |
| Cordis US CORP. | 1 | $19 |
| Cardiva Medical, Inc. | 1 | $17 |
| Teleflex LLC | 1 | $16 |
| Scpharmaceuticals Inc. | 1 | $15 |
| Bayer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Resolute$2,199
- VersaCross Access Solution$1,857
- WATCHMAN Access System$1,332
- JARDIANCE$239
- COREVALVE EVOLUT R$146
- GENERAL VASCULAR ACCESS$125
- PERCLOSE PROGLIDE$121
- Azure$114
How this compares
$12,165 in reported general payments places this provider in the 85th percentile of 198 cardiovascular disease providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,245 | $1,339,689 |
| XareltoRivaroxaban | 198 | $249,733 |
| Repatha SureclickEvolocumab | 271 | $225,496 |
| EntrestoSacubitril/Valsartan | 177 | $180,887 |
| FarxigaDapagliflozin Propanediol | 165 | $133,885 |
| JardianceEmpagliflozin | 103 | $114,152 |
| MultaqDronedarone Hcl | 52 | $72,744 |
| BrilintaTicagrelor | 89 | $53,773 |
| Praluent PenAlirocumab | 38 | $34,565 |
| VascepaIcosapent Ethyl | 26 | $19,300 |
| Ranolazine ErRanolazine | 248 | $18,729 |
| Metoprolol Succinate | 1,451 | $15,744 |
| Atorvastatin Calcium | 1,261 | $15,148 |
| Rosuvastatin Calcium | 869 | $12,694 |
| NexletolBempedoic Acid | 23 | $11,998 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $507 | $1,339,6891,245 claims |
| Johnson & JohnsonXarelto | $267 | $249,733198 claims |
| AstraZenecaFarxiga, Brilinta | $555 | $187,659254 claims |
| NovartisEntresto | $367 | $180,887177 claims |
| Boehringer IngelheimJardiance | $608 | $114,152103 claims |
| Sanofi-aventis U.S. LLCMultaq | $82 | $72,74452 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 198 cardiovascular disease providers in Oregon.
Other cardiovascular disease in Salem
- Kamran GhaliliSalem$11K
- Harminder GandhokSalem$8K
- Deborah HughesSalem$8K
- Raghunandan KamineniSalem$5K
- Ivan ArenasSalem$2K
- Firas ZahrPortland$810K
- Kathy GreweHood River$376K
- Scott ChadderdonPortland$282K
- Ahmad MasriPortland$227K
- Ashwat DhillonCorvallis$156K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.